ACD Pharma is a Norwegian R&D company that is at the forefront in the development of bacteriophage products. The company is currently in the process of establishing a large-scale bacteriophage production facility.
ACD Pharma
About us
ACD Pharma develops bacteriophage-based solutions as sustainable alternatives to antibiotics. The company is a global pioneer, having launched the world’s first phage product for aquaculture and continues to expand its pipeline and research footprint.
ACD Pharma has research facilities at Lofoten Bio Centre in Leknes as well as at the University of Life Sciences in Ås. The company is owned by Nordly Holding.